Vertex Pharmaceuticals (VRTX) Research & Development (2009 - 2026)

Vertex Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $961.6 million for Q1 2026.

• In Q1 2026, Research & Development fell 1.85% year-over-year to $961.6 million; the TTM figure through Mar 2026 stood at $3.9 billion (up 1.85% YoY), while the FY2025 annual figure was $3.9 billion, up 7.69% from the prior year.
• Research & Development was $961.6 million for Q1 2026 at Vertex Pharmaceuticals, down from $973.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $998.7 million in Q4 2024 to a low of $600.1 million in Q2 2022.
• Historically, Research & Development has averaged $835.6 million across 5 years, with a median of $824.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 38.12% in 2022, then decreased 2.5% in 2025.
• A 5-year view of Research & Development shows it stood at $694.1 million in 2022, then climbed by 18.8% to $824.6 million in 2023, then gained by 21.11% to $998.7 million in 2024, then dropped by 2.5% to $973.7 million in 2025, then declined by 1.24% to $961.6 million in 2026.
• The last three Research & Development figures came in at $961.6 million (Q1 2026), $973.7 million (Q4 2025), and $977.7 million (Q3 2025), per Business Quant data.